Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus METOPROLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus METOPROLOL.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs Metoprolol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Selective beta-1 adrenergic receptor antagonist; competitively blocks beta-1 receptors in the heart, decreasing heart rate, contractility, and cardiac output; reduces renin release from kidneys.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
Metoprolol tartrate: Initial 50 mg PO BID or 100 mg PO daily; maintenance 100-450 mg/day in divided doses. Metoprolol succinate (extended-release): Initial 25-100 mg PO once daily; maintenance 100-400 mg once daily.
None Documented
None Documented
Clinical Note
moderateMetoprolol + Digoxin
"Metoprolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateMetoprolol + Digitoxin
"Metoprolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateMetoprolol + Deslanoside
"Metoprolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateMetoprolol + Acetyldigitoxin
"Metoprolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
3–7 hours for metoprolol; prolonged in poor CYP2D6 metabolizers (up to 8–16 hours). Clinical context: dosing interval typically twice daily (immediate-release) or once daily (extended-release).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Primarily hepatic metabolism (CYP2D6) producing inactive metabolites; renal excretion accounts for <5% unchanged. Fecal elimination minimal.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker